RATIONALE: Given that many patients being treated for opioid-use disorder continue to use drugs, identifying clusters of patients who share similar patterns of use might provide insight into the disorder, the processes that affect it, and ways that treatment can be personalized. OBJECTIVES AND METHODS: We applied hierarchical clustering to identify patterns of opioid and cocaine use in 309 participants being treated with methadone or buprenorphine (in a buprenorphine-naloxone formulation) for up to 16 weeks. A smartphone app was used to assess stress and craving at three random times per day over the course of the study. RESULTS: Five basic patterns of use were identified: frequent opioid use, frequent cocaine use, frequent dual use (opioids and cocaine), sporadic use, and infrequent use. These patterns were differentially associated with medication (methadone vs. buprenorphine), race, age, drug-use history, drug-related problems prior to the study, stress-coping strategies, specific triggers of use events, and levels of cue exposure, craving, and negative mood. Craving tended to increase before use in all except those who used sporadically. Craving was sharply higher during the 90 min following moderate-to-severe stress in those with frequent use, but only moderately higher in those with infrequent or sporadic use. CONCLUSIONS: People who share similar patterns of drug-use during treatment also tend to share similarities with respect to psychological processes that surround instances of use, such as stress-induced craving. Cluster analysis combined with smartphone-based experience sampling provides an effective strategy for studying how drug use is related to personal and environmental factors.
RATIONALE: Given that many patients being treated for opioid-use disorder continue to use drugs, identifying clusters of patients who share similar patterns of use might provide insight into the disorder, the processes that affect it, and ways that treatment can be personalized. OBJECTIVES AND METHODS: We applied hierarchical clustering to identify patterns of opioid and cocaine use in 309 participants being treated with methadone or buprenorphine (in a buprenorphine-naloxone formulation) for up to 16 weeks. A smartphone app was used to assess stress and craving at three random times per day over the course of the study. RESULTS: Five basic patterns of use were identified: frequent opioid use, frequent cocaine use, frequent dual use (opioids and cocaine), sporadic use, and infrequent use. These patterns were differentially associated with medication (methadone vs. buprenorphine), race, age, drug-use history, drug-related problems prior to the study, stress-coping strategies, specific triggers of use events, and levels of cue exposure, craving, and negative mood. Craving tended to increase before use in all except those who used sporadically. Craving was sharply higher during the 90 min following moderate-to-severe stress in those with frequent use, but only moderately higher in those with infrequent or sporadic use. CONCLUSIONS: People who share similar patterns of drug-use during treatment also tend to share similarities with respect to psychological processes that surround instances of use, such as stress-induced craving. Cluster analysis combined with smartphone-based experience sampling provides an effective strategy for studying how drug use is related to personal and environmental factors.
Authors: Sarah A Edwards; Susan J Bondy; Matthew Kowgier; Paul W McDonald; Joanna E Cohen Journal: Nicotine Tob Res Date: 2010-10-26 Impact factor: 4.244
Authors: Melody Furnari; David H Epstein; Karran A Phillips; Michelle L Jobes; William J Kowalczyk; Massoud Vahabzadeh; Jia-Ling Lin; Kenzie L Preston Journal: Psychopharmacology (Berl) Date: 2015-07-09 Impact factor: 4.530
Authors: David H Epstein; Matthew Tyburski; Ian M Craig; Karran A Phillips; Michelle L Jobes; Massoud Vahabzadeh; Mustapha Mezghanni; Jia-Ling Lin; C Debra M Furr-Holden; Kenzie L Preston Journal: Drug Alcohol Depend Date: 2013-09-14 Impact factor: 4.492
Authors: Edward S Friedman; Lori L Davis; Sidney Zisook; Stephen R Wisniewski; Madhukar H Trivedi; Maurizio Fava; A John Rush Journal: Eur Neuropsychopharmacol Date: 2011-09-14 Impact factor: 4.600
Authors: Jennifer D Ellis; Chung Jung Mun; David H Epstein; Karran A Phillips; Patrick H Finan; Kenzie L Preston Journal: Neuropsychopharmacology Date: 2022-06-06 Impact factor: 8.294
Authors: Lisa A Marsch; Ching-Hua Chen; Sara R Adams; Asma Asyyed; Monique B Does; Saeed Hassanpour; Emily Hichborn; Melanie Jackson-Morris; Nicholas C Jacobson; Heather K Jones; David Kotz; Chantal A Lambert-Harris; Zhiguo Li; Bethany McLeman; Varun Mishra; Catherine Stanger; Geetha Subramaniam; Weiyi Wu; Cynthia I Campbell Journal: Front Psychiatry Date: 2022-04-29 Impact factor: 5.435
Authors: Julianne L Price; Marsha E Bates; Anthony P Pawlak; Sarah Grace Uhouse; Sabrina M Todaro; Julie Morgano; Jennifer F Buckman Journal: Front Psychiatry Date: 2022-09-07 Impact factor: 5.435
Authors: Albert J Burgess-Hull; Kirsten E Smith; Destiny Schriefer; Leigh V Panlilio; David H Epstein; Kenzie L Preston Journal: Drug Alcohol Depend Date: 2021-06-25 Impact factor: 4.852